CommentEdaravone: a new treatment for ALS on the horizon?
References (7)
- et al.
Amyotrophic lateral sclerosis: moving towards a new classification system
Lancet Neurol
(2016) - et al.
Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice
Exp Neurol
(2008) - et al.
Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study)
Amyotroph Lateral Scler
(2006)
There are more references available in the full text version of this article.
Cited by (61)
Masitinib: The promising actor in the next season of the Amyotrophic Lateral Sclerosis treatment series
2023, Biomedicine and PharmacotherapyPain Phenotypes in Rare Musculoskeletal and Neuromuscular Diseases
2021, Neuroscience and Biobehavioral ReviewsCitation Excerpt :The variability in terms used by patients to describe their discomfort highlights the complexity of pain in ALS and suggests the need for careful questioning on the part of providers when investigating symptoms in these patients. FDA-approved treatments for ALS include riluzole, dextromethorphan/quinidine, and recently edaravone (Hardiman and van den Berg, 2017; Writing and Edaravone, 2017), which have been shown to improve survival (Miller et al., 2012), provide relief from pseudobulbar symptoms (Brooks et al., 2004), and improve functioning (Hardiman and van den Berg, 2017; Writing and Edaravone, 2017). To date, there are no RCTs of pain management in ALS (Brettschneider et al., 2013).
Progress in progestin-based therapies for neurological disorders
2021, Neuroscience and Biobehavioral Reviews
© 2017 Elsevier Ltd. All rights reserved.